Find Clinical Trial
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
← Back
| Study Phase |
Phase 1-2 |
| Therapeutic Area |
Cancers |
| Indication | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome |
| Sponsor | Servier Bio-Innovation LLC |
| Active substance/ Medical device |
S227928 |
| Active Substance Code | S227928 |
| Protocol Code | S227928-180 |
| NCT Code | NCT06563804 |
Documents and links
| Results are not yet available. |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2025 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
